Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Theradiag
  6. News
  7. Summary
    ALTER   FR0004197747

THERADIAG

(ALTER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

THERADIAG Announces the Launch of 4 New i-Tracker? Kits and the Validation of a New Parameter in the United States

12/02/2021 | 11:45am EST

THERADIAG announced the launch of four additional kits in its i-Tracker? tests range and the validation of a new parameter in the United States, all dedicated to biotherapy monitoring. In addition to its eight kits that have already received CE marking1, Theradiag is expanding its range with 4 more kits of i-Tracker? tests: i-Tracker? Golimumab, i-Tracker? Anti-Golimumab, i-Tracker? Rituximab and i-Tracker? Anti-Rituximab, all of which being adapted to its latest generation random-access analyzer i-Track10? and the IDS-iSYS automated system manufactured by the company IDS.


ę S&P Capital IQ 2021
All news about THERADIAG
01/13Theradiag Signs PCR Test Distribution Agreement With Biosynex
MT
2021THERADIAG Announces the Launch of 4 New i-Tracker? Kits and the Validation of a New Par..
CI
2021France's Biosynex Raises Theradiag Stake to Nearly 19%
MT
2021Theradiag Raises $5 Million Via Rights Issue To Fund Expansion
MT
2021Theradiag Slumps 21% on Launch of $6 Million Rights Issue
MT
202126/10/2021 : Theradiag launches a Rights Issue
PU
2021Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021THERADIAG : Half-year results
CO
2021GLOBAL MARKETS LIVE : Zoom, Facebook, Toyota, Canon, Partners Group...
202119/07/2021 : Theradiag reports revenue of Ç5.5 million for the first half of 2021, up 12.5..
PU
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 91,3x
Yield 2021 -
Capitalization 27,6 M 31,3 M 31,3 M
Capi. / Sales 2021 -
EV / Sales 2022
Nbr of Employees 59
Free-Float 99,1%
Chart THERADIAG
Duration : Period :
Theradiag Technical Analysis Chart | ALTER | FR0004197747 | MarketScreener
Technical analysis trends THERADIAG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,12 €
Average target price 2,48 €
Spread / Average Target 17,1%
Managers and Directors
Bertrand Michel Marle de Castelnau Chief Executive Officer & Director
Muriel Bardet Chief Financial Officer
Pierre Armand Morgon Chairman
Sylvie Bratel Independent Director
Vincent Fert Director
Sector and Competitors
1st jan.Capi. (M$)
THERADIAG-10.62%31
EXACT SCIENCES CORPORATION-2.18%13 119
GUARDANT HEALTH, INC.-28.01%7 319
BGI GENOMICS CO., LTD.5.02%5 957
INVITAE CORPORATION-26.92%2 526
ADAPTIVE BIOTECHNOLOGIES CORPORATION-37.56%2 473